Review · United States
Afamelanotide
Reviewed on
Approval and product status
An FDA-approved implant exists for a rare-disease indication
Scenesse is not the same as every tanning peptide or injection. Scenesse is a healthcare-professional-administered implant. It is not equivalent to tanning peptides, compounded injections, or other melanocortin analogues.
What was measured in people?
- Health results · Strong
- Randomized trials support pain-free light-exposure and quality-of-life outcomes in adults with EPP.
- Body changes · Strong
- The approved implant's pharmacology and melanocortin-1 activity are characterized.
A change in a hormone or body signal does not by itself prove a health benefit.
Important limits
This tool is not an independent medical review. It does not recommend treatment.
The implant is administered by trained healthcare professionals and the label calls for skin monitoring. This guide provides no implant or cosmetic-use instructions.
Still unknown: The approval does not establish general tanning, cosmetic anti-aging, athletic, or other disease benefits. It does not validate different melanocortin peptides.
This record cannot check a package, seller, batch, or personal treatment. It does not provide sport clearance.
Approval fact checks
“Scenesse is an approved cosmetic tanning implant.”
Misleading. Its approval is for pain-free light exposure in adults with EPP, not cosmetic tanning.
Applies to: The current FDA-approved indication.
Products in this review
These are selected records, not every product or form.
Scenesse
- Ingredients and form
- Controlled-release implant
- How it enters the body
- Implant under the skin, placed by a trained professional
- Use and people covered
- Increase pain-free light exposure in adults with erythropoietic protoporphyria and a history of phototoxic reactions.
Published label: 2024 label
Read the published Scenesse FDA label (PDF)What the research shows
Randomized trials in erythropoietic protoporphyria, or EPP, reported more pain-free light exposure and improvements in disease-specific quality of life. FDA approved Scenesse for a corresponding adult population.
Read all Afamelanotide fact checksSources used in this review
A source may support some statements, not all of them. Use the links above or this review to see what each source supports.
Show 3 sources
- SCENESSE (afamelanotide) prescribing information
U.S. Food and Drug Administration · Drug label · 2024
Source accessed
- Afamelanotide for erythropoietic protoporphyria
PubMed · New England Journal of Medicine · Randomized trial · 2015
Source accessed
- Afamelanotide orphan drug designation and approval
U.S. Food and Drug Administration · Regulatory · 2019
Source accessed